Screener
Veradermics MANE Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Veradermics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands, except share and per share amounts) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total other income, net | 2,630 | 515 |
| Loss before income taxes | (27,232) | (12,400) |
| Income tax benefit | — | — |
| Net loss | $(27,232) | $(12,400) |
| Net loss attributable to common stock | $(30,011) | $(14,582) |
| Net loss per share of common stock, basic and diluted | $(1.32) | $(19.79) |
| Weighted average common stock outstanding, basic and diluted | 22,704,124 | 736,933 |
| Other comprehensive loss: |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics's net income?
- Veradermics (MANE) reported net income of -$27.23M in Q1 2026.
- How has Veradermics's net income changed year-over-year?
- Veradermics's net income decreased by 119.6% year-over-year, from -$12.4M to -$27.23M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Veradermics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude